Strs Ohio Decreases Position in Lantheus Holdings, Inc. $LNTH

Strs Ohio cut its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 91.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,900 shares of the medical equipment provider’s stock after selling 40,300 shares during the period. Strs Ohio’s holdings in Lantheus were worth $200,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Elevation Point Wealth Partners LLC purchased a new stake in Lantheus during the 2nd quarter valued at about $26,000. First Horizon Corp bought a new stake in Lantheus in the third quarter valued at approximately $26,000. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus during the second quarter valued at approximately $36,000. Tripletail Wealth Management LLC bought a new position in shares of Lantheus in the third quarter worth approximately $68,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after buying an additional 698 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on LNTH shares. Truist Financial increased their price target on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Mizuho boosted their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the stock a “neutral” rating in a report on Wednesday, October 8th. Finally, Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Stock Performance

Shares of LNTH stock opened at $66.50 on Tuesday. The company’s fifty day moving average price is $65.07 and its 200-day moving average price is $59.72. The stock has a market cap of $4.41 billion, a PE ratio of 27.94 and a beta of -0.08. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.29.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The company had revenue of $384.01 million during the quarter, compared to analysts’ expectations of $363.42 million. During the same period last year, the company posted $1.70 EPS. Lantheus’s revenue was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. On average, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.